HASAN ÇAĞRI YILDIRIM
Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalı
Araştırma alanları: Sağlık Bilimleri
Yayınlar
- Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study (2026)
- The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer (2026)
- Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study (2026)
- Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG) (2026)
- Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis (2026)
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study (2026)
- Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers (2026)
- Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group (2026)
- Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey (2026)
- Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study (2026)
- Real-World Outcomes Of HER2-Positive Metastatic Gastric Cancer Patients Treated With Trastuzumab-Based Therapy: A Single-Center Experience (2025)
- Body Mass Index as an Independent Prognostic Factor in Second-Line Nivolumab Therapy for Metastatic Clear Cell Renal Cell Carcinoma (2025)
- Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group (2025)
- A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications (2025)
- HERC2 as a Potential Biomarker for Prognosis and Response to Bevacizumab in Ovarian Cancer: A Bioinformatics Approach (2025)
- CPNE2 might serve as a new negative prognostic biomarker in gastric cancer (2025)
- Dynamine 3 as a diagnostic and prognostic biomarker in pancreatic cancer: Implications for early detection and targeted therapy (2025)
- Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score (2025)
- Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel (2025)
- RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025)
- Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey (2025)
- Prognostic value of the StAN score in elderly small cell lung cancer (2025)
- Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS study (2025)
- Prognostic Impact of Glomerular Filtration Rate Decline on Survival Outcomes in Metastatic Renal Cell Carcinoma Treated with Targeted Therapy (2025)
- Prognostic Impact of Pre-Treatment Modified Glasgow Prognostic Score (mGPS) on Survival in Patients with Advanced-Stage Ovarian Cancer (2025)
- Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines (2025)
- Real-World Pathologic Complete Response Rates with Neoadjuvant Pembrolizumab in Stage II–III Triple-Negative Breast Cancer: Impact of Ki-67 Proliferation Index (2025)
- Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG) (2025)
- A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value (2025)
- Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group (2025)
- Adjuvant Gemcitabine-cisplatin Combination for Biliary Tract Cancer: A Real Life Experience (2025)
- Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study (2025)
- Prognostic and predictive significance of the pan-immune-inflammation value in endometrial cancer patients undergoing adjuvant therapy (2025)
- Bioinformatics Analysis of IGSF9B Gene in Patients Diagnosed with Colorectal Carcinoma (2025)
- Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study. (2025)
- 2651P Real-world comparison of Cabozantinib and Sunitinib in advanced non–clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group (TOG) (2025)
- The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer (2025)
- 67P Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma (2024)
- The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer (2024)
- Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma (2024)
- Sirolimus experience in adult patients with vascular malformations (2024)
- The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study (2024)
- The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study (2024)
- CXCL10, SCGN, and H2BC5 as Potential Key Genes Regulated by HCV Infection (2024)
- Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey (2024)
- Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer (2024)
- Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study (2024)
- KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer (2024)
- Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy (2024)
- Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab (2024)
- Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program-LynTurk study (2023)
- Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study (2023)
- Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer (2023)
- Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey (2023)
- KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer (2023)
- Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort (2023)
- The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma (2023)
- SMART syndrome: a case report (2023)
- The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors (2023)
- Advances in the Early Detection of Hepatobiliary Cancers (2023)
- PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study (2023)
- A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer (2023)
- Acute heart failure following pazopanib treatment: a literature review featuring two case reports (2023)
- Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment (2023)
- A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology (2023)
- Geriatrik (≥65 Yaş) Meme Kanseri Hastalarında CDK 4/6 İnhibitörlerine Bağlı Toksisiteler Ve Yönetimi, Bir Prospektif Tog Çalışması (2022)
- Neoadjuvant Chemotherapy Data in Signet Ring Cell Gastric Carcinoma (2022)
- Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study (2022)
- Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study (2022)
- Detailed Analysis of Follicular Lymphoma over 25 Years: A Single-Center, Retrospective Study (2022)
- HER2-low breast cancer could be associated with an increased risk of brain metastasis (2022)
- Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy (2022)
- The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors (2022)
- The burden of polypharmacy and drug–drug interactions in older cancer patients treated with immunotherapy (2022)
- Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group) (2022)
- The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy (2022)
- Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease (2022)
- Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study (2022)
- Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study (2022)
- Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy (2022)
- Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy (2022)
- The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study (2022)
- Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review (2022)
- Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study (2022)
- Real Life Experience of Patients With Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Treated With Neoadjuvant Chemotherapy: a Turkish Oncology Group Study (2021)
- Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study. (2021)
- Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery a real-world study by Turkish oncology group (2021)
- Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery (2021)
- Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma (2021)
- Impact of Coronaphobia on Treatment and Follow-Up Compliance of Cancer Patients (2021)
- Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic (2021)
- PILE: a candidate prognostic score in cancer patients treated with immunotherapy (2021)
- Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy (2021)
- The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy (2021)
- Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors (2021)
- A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer (2021)
- Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality (2021)
- Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19 (2020)
- Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report (2020)
- Alterations in muscle strength among patients with GI cancers receiving oral nutritional support as soon as malnutrition was detected: ONMUS study.